Can Matinas BioPharma (MTNB) avoid delisting while trying to salvage MAT2203?

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) said it received a notice from NYSE American on April 2, 2026, stating that the company no longer meets continued listing standards tied to minimum stockholders’ equity. The trigger is straightforward but serious: Matinas BioPharma ended 2025 with $4.83 million in stockholders’ equity, below the $6 million threshold applied to issuers that have posted losses in each of their five most recent fiscal years. The company has until May 2, 2026 to submit a compliance plan and could receive up to 18 months to regain compliance if that plan is accepted. For a company with a market value still measured in the single-digit millions and a lingering going-concern warning, this is less a paperwork event than a financing and survival test.

Why did Matinas BioPharma Holdings, Inc. receive a NYSE American non-compliance notice in April 2026?

The technical reason is that Matinas BioPharma fell short of the exchange’s equity thresholds under Section 1003(a) of the NYSE American Company Guide. Those standards scale based on how persistent a company’s losses have been. In Matinas BioPharma’s case, five consecutive fiscal years of losses pushed the relevant threshold to $6 million, while the company disclosed stockholders’ equity of $4.83 million as of December 31, 2025. The exchange also said the company is not currently eligible for an exemption under that section.

That matters because the notice is not simply about a weak share price or a temporary trading glitch. It is balance-sheet driven. For early-stage biotechnology companies, exchange compliance issues often reflect a deeper capital structure problem: cash burn has outrun near-term catalysts, while the equity cushion needed to remain listed has eroded faster than management can replenish it. In plain English, Wall Street is not just questioning valuation here. The exchange is questioning whether the corporate shell still has enough balance-sheet support to justify its current market venue.

What does the NYSE American warning mean for Matinas BioPharma Holdings, Inc. beyond the headline risk?

The company stressed that the notice has no immediate effect on trading and does not alter its business operations or Securities and Exchange Commission reporting obligations. That is true as far as it goes. If NYSE American accepts Matinas BioPharma’s remediation plan, the shares can keep trading on the exchange during the cure period, subject to quarterly reviews. But that “no immediate impact” language can sometimes lull retail investors into missing the real issue. The threat is not today’s listing status. It is the narrowing set of credible paths to restore compliance without inflicting further dilution or shrinking the business into irrelevance.

Matinas BioPharma’s own 10-K makes that risk explicit. The filing says the company’s auditor included an explanatory paragraph raising substantial doubt about its ability to continue as a going concern. The same annual report also notes a history of prior NYSE American compliance problems, including earlier low-price issues, a trading halt in 2024 before a reverse stock split, and an annual meeting deficiency resolved in June 2025. That pattern does not guarantee delisting now, but it does show the latest notice is arriving after multiple earlier stress signals. This is becoming a recurring governance and capital markets story, not a one-off compliance hiccup.

How does this NYSE American notice change the funding outlook for Matinas BioPharma Holdings, Inc. and MTNB stock?

For Matinas BioPharma, the most immediate implication is that every financing decision now carries two jobs. It must extend runway and also help satisfy exchange standards. Those are not always the same thing. A financing that adds cash but crushes the stock through aggressive dilution can create a new problem even as it solves another. Conversely, a strategic transaction that validates MAT2203 but arrives too late may not prevent delisting pressure from intensifying.

The company’s 10-K already outlined how dependent it is on securing partners, controlling expenses, using equity-linked financing, or pursuing broader strategic alternatives. Last year’s termination of negotiations under a non-binding term sheet for global licensing rights to MAT2203 was especially damaging because it undercut what might have been the cleanest route to value realization. Management responded with an 80% workforce reduction and the suspension of certain development activities to preserve cash while evaluating a sale of MAT2203 and other alternatives, including a possible winddown or dissolution. That history explains why the exchange notice lands so hard: Matinas BioPharma is not facing a compliance problem while advancing from strength. It is facing one after a failed partnering track already forced a major retrenchment.

Why is MAT2203 still central to whether Matinas BioPharma Holdings, Inc. can regain investor confidence?

The company remains built around the proposition that its lipid nanocrystal platform can make oral delivery of amphotericin B viable through MAT2203, potentially reducing toxicity relative to intravenous formulations. On paper, that is still the strategic asset. The company says MAT2203 met the primary endpoint in the completed Phase 2 EnACT study in cryptococcal meningitis and had been planned for a Phase 3 registration trial in invasive aspergillosis patients with limited treatment options. But platform promise alone does not restore listing compliance. The market now needs evidence that MAT2203 can attract either a credible partner, a buyer, or a financing package tied to believable clinical and regulatory execution.

This is where biotech valuation gets brutally binary. A small clinical-stage company can live with accounting losses for years if investors believe the lead asset is financeable and strategically relevant. Once that belief weakens, exchange compliance becomes a symptom of collapsing optionality. The product may still have scientific merit, but the company’s negotiating leverage falls fast when counterparties know time, capital, and listing status are all under pressure.

What is the market saying about Matinas BioPharma Holdings, Inc. after the non-compliance notice?

MTNB closed around the mid-$0.50 range in the latest pricing data, with a 52-week range of roughly $0.47 to $3.09. The company’s market capitalization is now only a few million dollars by several public market data sources, underscoring how little equity value investors are assigning to the remaining platform and pipeline optionality. Recent performance figures from market data services show the stock down over both the past five trading days and the past month, which suggests the exchange notice is hitting a name that was already under severe pressure rather than blindsiding a stable small-cap story.

That sentiment makes sense. The market appears to be pricing Matinas BioPharma less as a going-concern growth biotech and more as a distressed strategic optionality case. Investors are effectively asking whether there is a monetizable asset left before listing risk, financing dilution, or corporate restructuring overtakes the science. Biotech traders love upside. They just prefer it with enough cash to survive until the next catalyst. Right now, Matinas BioPharma looks like a story where the runway is stealing the spotlight from the molecule.

What happens next if Matinas BioPharma Holdings, Inc. cannot satisfy NYSE American continued listing standards?

The near-term milestone is the compliance plan due by May 2, 2026. If NYSE American accepts that plan, Matinas BioPharma may continue trading during the cure period while the exchange monitors progress. If the plan is rejected, delisting proceedings can begin, though the company would have appeal rights under exchange rules.

The bigger question is what the plan actually contains. Investors should watch for three things. First, does management present a concrete capital-raising or balance-sheet repair strategy rather than generic language about exploring alternatives? Second, does MAT2203 attract a partner or transaction structure that validates external interest? Third, can Matinas BioPharma avoid a spiral in which repeated compliance events further weaken investor confidence and raise the eventual cost of capital?

If management can produce a credible recapitalization path and attach it to a strategic future for MAT2203, the current notice may end up being remembered as a painful but survivable checkpoint. If not, the company risks drifting from listed clinical-stage biotech into a much harsher category: an asset sale or restructuring story where the exchange notice was simply the warning flare investors chose not to ignore.

What are the key takeaways from Matinas BioPharma Holdings, Inc.’s NYSE American non-compliance notice for MTNB investors and biotech peers?

• Matinas BioPharma’s NYSE American notice is fundamentally a balance-sheet problem, not just a trading-price issue.
• The company’s $4.83 million in stockholders’ equity fell below the $6 million threshold applied to issuers with losses in each of the last five fiscal years.
• The May 2, 2026 compliance-plan deadline is now the key near-term catalyst for MTNB holders.
• Continued exchange trading is still possible during the cure period, but only if NYSE American accepts the company’s remediation plan.
• The going-concern warning in the 2025 annual report sharply increases the importance of any financing or strategic transaction.
• MAT2203 remains the core asset, but platform promise will not matter unless it can be converted into funding, partnership interest, or a sale.
• Prior exchange compliance episodes make this latest notice look like part of a broader deterioration in capital-markets resilience.
• Any recapitalization that restores compliance but destroys shareholder value through heavy dilution could solve one problem while worsening another.
• MTNB’s small market capitalization and depressed share price suggest investors are already discounting severe execution and funding risk.
• For biotech peers, Matinas BioPharma is a reminder that exchange compliance often becomes the visible consequence of a much deeper financing breakdown.